urea has been researched along with Parkinson Disease, Secondary in 2 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "N-carbamoyl-2-(2,6-dichlorophenyl) acetamidine hydrochloride (LON 954) causes a reproducible rest tremor in mice, of rapid onset and short duration with no associated rigidity or akinesia and in the absence of any marked changes in body temperature or accompanying peripheral parasympathomimetic effects." | 3.65 | The production of an alternative laboratory model of the Parkinson syndrome using a new benzylimidoylurea derivative LON 954. ( Coward, DM; Doggett, NS, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fox, SH | 1 |
| Moser, B | 1 |
| Brotchie, JM | 1 |
| Coward, DM | 1 |
| Doggett, NS | 1 |
2 other studies available for urea and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopamine Agonists; Excitatory Amino Acid Antagoni | 1998 |
The production of an alternative laboratory model of the Parkinson syndrome using a new benzylimidoylurea derivative LON 954.
Topics: Animals; Antiparkinson Agents; Benzimidazoles; Disease Models, Animal; Drug Evaluation, Preclinical; | 1977 |